BMI View: The already modest attractiveness of Namibia’s pharmaceutical, medical device and healthcare markets has declined slight

BMI View: While the Netherlands is a low risk market from the point of view of multinational drugmakers, the country’s modest per

BMI View: We do not expect Taiwan's healthcare expenditure to reach the government's target of 7.5% of GDP in the short to medium

BMI View: Cameroon’s medium-to-long-term drug market expansion potential remains highly dependent on the country’s economic growth

BMI View: The pharmaceutical markets of Central America, when viewed collectively, represent small but growing proposition to drug

BMI View: Healthcare may not have been a major concern for Angola’s government – which has prioritised economic development over s

BMI View: Mexico offers significant and improving opportunities for multinational pharmaceutical companies, especially in the outp

BMI View: Before 2010, Turkey's pharmaceutical market growth was rapidly driven by modernisation, growing investment and improving

BMI View: It is vital the Tanzanian government assesses its medicine procurement systems. The expiry of medicines does not bode we

BMI View: We have revised downwards our 2012 projections for the growth of the Latvian pharmaceutical market on account of weaker

BMI View: The Nigerian pharmaceutical market continues to be seen as a risky proposition to multinationals. While the country’s oi

BMI View: Given the country’s increasingly ageing population and the consequential rise in noncommunicable diseases, Australia is

BMI View: Our five-year forecasts for the Swedish pharmaceutical market show a decline in its overall size, which is expected to f

BMI View: While it is clear the implementation of a medicine pricing policy will help to control public pharmaceuticals and health

BMI View: We continue to believe the Belarusian pharmaceutical market has long-term potential due to the country’s favourable geog

BMI View: Venezuela’s pharmaceutical industry will face increasingly harsh pricing policy which is unlikely to tackle the persiste

BMI View: New population data for 2011 show the size of the expatriate population in the United Arab Emirates (UAE) has been under

BMI View: Lithuania’s drug market is expected to post a gradual recovery over the next five years, but with a short-term worsening

BMI View: South Africa is one of the most developed markets in the region from a business environment and regulatory standpoint. H

BMI View: The Iraqi government aims to encourage more foreign investment in the country’s healthcare system, with a recent report

BMI View: The Association of Southeast Asia Nations (ASEAN) is becoming increasingly attractive to foreign investors given the ass

BMI View: Belgium, much like most of the other regional markets, is expected to post negative year-onyear (y-o-y) value growth in

BMI View: India’s pharmaceutical market is highly attractive to drugmakers but it also has several negative characteristics. Combi

BMI View: The attractiveness of the Vietnamese pharmaceutical market to foreign investors will continue to be hampered by the coun

BMI View: While the strength of the UK’s pharmaceutical manufacturing industry is significant, the sector will face considerable c

The Slovakian pharmaceutical market will be shaped by the introduction of new, strict costcontainment measures, which include legi

BMI View: Morocco’s pharmaceutical and healthcare market developments this year will be shaped by the delayed rollout of the natio

BMI View: Chile’s pharmaceutical market is expected to become an increasingly attractive proposition for multinational companies a

BMI View: While Ghana’s business environment is superior to that of almost all of its neighbours in West and Central Africa, its d

BMI View: The challenges facing drugmakers in Greece in 2012 will be considerably tougher than those faced in 2011. With the intro

BMI View: We retain our negative outlook for the pharmaceutical market in the Czech Republic, expecting a 1.8% contraction in its

BMI View: In line with BMI’s view that public healthcare spending in Saudi Arabia would be greatly / boosted by government initiat

BMI View: Bahrain is a developed pharmaceutical market with patented drug spending accounting for / over 83% of the total pharmace

BMI View: 2012 is a very important year for the country as the government look to carry on their / achievements following the heal

BMI View: Brazil remains the most attractive emerging pharmaceutical market in the Americas due to its / large population, strong

BMI View: Corruption continues to be a major problem within state healthcare services in Serbia. The / government are taking measu

BMI View: On the positive side, Russia’s pharmaceutical market should regain double-digit US dollar / growth from 2013 and the app

BMI View: Indonesia is a high growth pharmaceutical market driven by rising domestic consumption / and government spending on heal

BMI View: Following widespread protests in mid-2011, the Israeli government has been under / significant pressure to spend more on

Sudan / BMI View: We maintain our view that the outlook for Sudan and South Sudan's pharmaceutical markets / will be more dependen

BMI View: While Kuwait will continue to be of interest to multinational drugmakers – on account of / traditional preference for br

BMI View: With Canada’s economy set to weather the external storm, the outlook for the country’s / pharmaceutical market looks rel

BMI View: Although the growth of Bangladesh’s pharmaceutical market is expected to remain in double / digits over the forecast per

BMI View: Continued improvement in Lebanon's intellectual property (IP) and pharmaceutical / regulatory environment reinforces BMI

BMI View: Malaysia’s longer term potential as an attractive pharmaceutical market will remain shaped by the / prevailing economic

BMI View: Moldova’s pharmaceutical market recorded stronger growth in 2011, but its small market / size and its status as the poor

BMI View: Puerto Rico is struggling to retain its reputation as a pharmaceutical manufacturing hub, / with a number of plants foun

BMI View: Since the approval of an EU/ECB/IMF economic rescue package in May 2011, cost cutting measures / have taken their toll o

BMI View: Following the resignation of Emil Boc and his government in February 2012, there is now / considerable uncertainty with

BMI View: Singapore is a well-developed pharmaceutical market, although overall sales only reached a / modest SGD901mn (US$716mn)

Angola / BMI View: Angola’s pharmaceutical and healthcare market is characterised by a weak regulatory / framework, a lack of inte

BMI View: Companies with significant exposure to debt-ridden European markets will be hard hit by / government austerity measures

BMI View: The expected growth of the Switzerland’s ageing population over the next 50 years will have / an unprecedented impact on

BMI View: While we continue to see huge potential in the Ukrainian pharmaceutical market, we are / pessimistic with regard to shor

BMI View: Economics and politics are increasingly exerting an influence on the US pharmaceutical / market. This is in stark contra

BMI View: The better regulated markets of the Gulf Cooperation Council (GCC), South Africa and Israel / will remain the most rewar

BMI View: Much of the population in the Philippines still struggles to afford medicines, despite the / enforcement of the Universa

BMI View: Oman’s 2012 budget allocated a greater sum of money to the healthcare sector, in line / with BMI’s view that the Arab sp

BMI View: Kazakhstan remains the most accessible and competitive pharmaceutical market in Central / Asia and the growing expectati

BMI View: Despite concerted progress made on the fiscal consolidation front in the first half of 2011, the / French government’s m

BMI View: Despite an increasingly ageing population (consequently increasing burden of noncommunicable / diseases) Hong Kong will

BMI View: It is worth reiterating our view that while 2012 is set to be a challenging year for drugmakers / operating in Poland, w

BMI View: On account of its unpredictable and unfavourable operating environment and limited funding / for and investment in healt

BMI View: Following Qatar’s decision to reintroduce controls on medicine prices in late 2011, we / expect pharmaceutical price inf

BMI View: Colombia’s pharmaceutical and healthcare markets will perform better than the regional / average over the medium term du

BMI View: Bulgaria’s pharmaceutical market will be under some pressure in 2012 due to a weakening / economic outlook and the tight

BMI View: We believe Zambia is rapidly becoming one of the most promising markets in Sub-Saharan Africa. An increased focus on hea

BMI View: Mozambique’s pharmaceutical market is typical of developing markets, with a poor regulatory framework, dependence upon d

BMI View: Japan’s pharmaceutical market is highly attractive to both foreign and local drugmakers. All three sub-sectors – patente

BMI View: Estonia’s pharmaceutical market will remain of marginal interest to multinationals given its small population and a mode

BMI View: In line with BMI’s expectation that free healthcare provision for all would be too expensive for Côte d’Ivoire, the gove

This Special Report from Business Monitor International (BMI) examines the African healthcare and pharmaceutical markets, looking

BMI View: It is our view that the Swiss economy will record slower growth in 2012. This may lead to the implementation of more aus

BMI View: Botswana has a relatively well-developed healthcare market. Despite its small population, the country has one of the hi

BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and

BMI View: Some changes have been made to the original March 2011 proposal to reduce costs in the pharmaceutical market, represent

BMI View: We continue viewing Iran as one of the less attractive regional markets. Imposition of more stringent international san

BMI View: The pharmaceuticals and healthcare sector will be a target of further cost containment, particularly as National Health

BMI View: While Egypt’s healthcare and pharmaceuticals industry outlook continues to be dominated by macroeconomic themes, such a

BMI View: Gabon’s pharmaceutical and healthcare market represents a small but growing opportunity to drugmakers and producers of

BMI View: Despite the fact a significant number of multinationals are present in Pakistan, and the country's significant market p

BMI View: Slovenia's pharmaceutical market outlook remains broadly unchanged in our Q212 assessment. While weak economic data and

BMI View: Thailand is a moderately attractive pharmaceutical market for multinationals. On the positive side, rewards are potentia

BMI View: Uganda's pharmaceutical market is typical of developing markets: defined by an absence of a clear regulatory framework,

BMI View: Uzbekistan’s pharmaceutical market remains one of the fastest growing in the Central and Eastern Europe (CEE) region an

BMI View: Based on Croatia’s deteriorating macroeconomic outlook, combined with our expectations that the new Kukuriku coalition

BMI View: New Zealand has slipped ranks in our latest Risk/Reward Ratings – falling behind India due to the fact its small pharma

BMI View: While South Korea's research and development (R&D) environment may be attractive to investors, its pharmaceutical marke

BMI View: We maintain our view that the outlook for Sudan and South Sudan's pharmaceutical markets will be more dependent on the

BMI View: The attractiveness of Jordan’s pharmaceutical and healthcare markets in the short term will be shaped by the prevailing

BMI View: Indonesia will continue to represent a high-risk but high-reward pharmaceutical market for multinationals, on account o

BMI View: While the Turkish pharmaceutical industry has achieved some concessions following additional price cuts and public disco

BMI View: Sweden’s high public expenditure on health (SEK252bn, or US$39bn, in 2011), accounting for 79% of total healthcare expen

BMI View: As the most populous country on the African continent, Nigeria should be of interest to multinational drugmakers. Howeve

BMI View: Theoretically, Mexico offers one of the most favourable intellectual property (IP) environments in Latin America, which

BMI View: The Kenyan pharmaceuticals and healthcare market presents significant revenue-earning opportunities for drug companies.

BMI View: Australia’s pharmaceutical sector will get increasingly more regulated as the government seeks to make improvements for

BMI View: Measured in local currency and in US dollars, the value of Argentina’s pharmaceutical market is expected to grow at doub

BMI View: Algeria is a high-risk market for multinational drugmakers because of the combination of regional uncertainty and state

BMI View: The Belarusian pharmaceutical market has strong long-term potential given its position bordering the EU and Russia, its

BMI View: Foreign pharmaceutical investors will place Cambodia low on their interest lists as the country is still plagued by corr

BMI View: Demographic considerations – in combination with concerted cost-containment pressures that form part of fiscal austerity

BMI View: South Africa's timescale for enacting its National Health Insurance (NHI) scheme is practical and achievable, as are the

BMI View: Sri Lanka’s pharmaceutical market is expected to post a 2010-2015 compound annual growth rate (CAGR) of 10.2%, as measur

The Three Tiers Of The MEA Region The countries of the Middle East and Africa (MEA) region vary greatly in the regulation of their

BMI View: The potential of the Slovakian pharmaceutical market in the short term has been subdued by recent legislative changes. T

BMI View: Brazil’s large population, combined with strong private consumption, bodes well for foreign drugmakers looking to capita

BMI View: At a value of CLP1,381bn (US$2.71bn), drug expenditure in Chile represented 1.32% of GDP in 2010, while per capita spend

BMI View: Ghana’s pharmaceutical market is expected to post double-digit year-on-year (y-o-y) growth again in 2011, which will par

BMI View: It is beyond doubt that drugmakers in Greece – particularly domestic producers primarily exposed to their home market –

BMI View: India’s pharmaceutical market will increasingly attract foreign drugmakers. The government has made a clear statement th

BMI View: According to the figures provided by l’Association Marocaine de l’Industrie Pharmaceutique (AMIP), drug expenditure in M

BMI View: Renewed liberalisation of Russia’s pharmaceutical market could follow the final approval of the country’s membership of

BMI View: We believe the Spanish government's austerity measures are a necessary and prudent course of action. The country still h

BMI View: Healthcare spending in the US will continue to account for a disproportionately large percentage of its GDP. Citizens of

BMI View: Despite strong growth potential, the government’s protectionist policy of preventing foreignowned companies from distrib

BMI View: The countries of the Gulf Cooperation Council (GCC) have plenty of opportunities for newly / established drug manufactu

BMI View: Economic growth will aid the development of Bangladesh’s pharmaceutical and healthcare / sectors as affordability level

BMI View: Moldova’s small market size and its status as the poorest countries in Europe limit its / attractiveness as a destinati

BMI View: Despite its steady growth over the past decade, Peru remains a relatively small / pharmaceutical market – valued at no

BMI View: As the world's most attractive emerging pharmaceutical market, the Chinese government's commitment to provide affordable

BMI View: Malaysia's growing domestic pharmaceutical market continues to attract drugmakers into the country. Increased private sp

BMI View: The Saudi market is extremely appealing to multinational drugmakers as it is set to experience rapid growth in demand fo

BMI View: Despite a downgrade in our economic outlook for Serbia, BMI's expenditure projections for the pharmaceutical market for

BMI View: While we believe cost constraints will hit the public healthcare system, it is highly unlikely the Canadian government w

BMI View: Despite the government’s focus on fiscal consolidation – which includes various costcontainment measures impacting the c

BMI View: Hong Kong continues to be viewed as a moderately attractive longer-term pharmaceutical market, largely on account of its

BMI View: Despite the government’s commitment to providing affordable medical treatment for the population, the vast majority of p

BMI View: We continue to see strong short and medium-term growth potential for the Ukrainian pharmaceutical market, with the cavea

BMI View: We view Germany as the fifth most attractive pharmaceutical market globally. A large population and the government’s con

BMI View: Our opinion that industrial action in Israel would result in an increase in public healthcare expenditure has played out

BMI View: Kuwait remains regarded as one of the strongest long-term prospects for foreign companies within the Middle East and Afr

BMI View: The expected growth of Belgium’s ageing population will have an unprecedented effect on the provision of healthcare. The

BMI View: Out-of-pocket spending will continue to be the main driver behind the growth of Bulgaria’s pharmaceutical market, though

BMI View: Under pressure from jittery financial markets, a new Italian government led by Prime Minister Mario Monti was sworn in o

BMI View: We remain convinced that Kazakhstan is the most accessible pharmaceutical market in Central Asia. The government has com

BMI View: While New Zealand has a highly developed healthcare services system, its pharmaceutical market is not a particularly att

BMI View: While Oman is viewed favourably in terms of operating risks, constraints on medicine pricing and the small population wi

BMI View: The EU/IMF economic rescue package, approved in May 2011, has widespread implications for the pharmaceutical sector, inc

BMI View: Puerto Rico has long held a reputation as a hotspot for foreign pharmaceutical investment, due to its low cost base and

BMI View: Qatar's attempt to introduce free market competition to its private drug distribution network has failed. Although the m

BMI View: The introduction of a revised claw-back mechanism in Romania has angered drugmakers operating in the market. BMI believe

BMI View: We commend initiatives launched by Singapore's government to ease the financial burden of healthcare on lower-income pat

BMI View: Zimbabwe’s pharmaceutical market will remain unattractive in the medium term due to its low value and unpredictable oper

BMI View: The attractiveness of the Lebanese pharmaceutical market is underpinned by the improving regulatory environment and the

The Hungarian petrochemicals industry reported strong export-led growth in H111, but BMI’s latest Hungary Petrochemicals Report st

BMI View: Algeria’s attractiveness to foreign drugmakers remains tarnished by the heightened political and security risks, despite

BMI View: As countries are expected to invest heavily in healthcare provision over the medium term, we forecast the pharmaceutical

BMI View: Iran remains a very risky pharmaceutical market, not least due to its unsettled political situation. Theoretically speak

BMI View: Japan’s pharmaceutical market is proving to be a welcome refuge for the leading multinational drugmakers, which are expe

BMI View: Regionally speaking, Jordan’s pharmaceutical market will continue to be viewed as a moderately attractive destination fo

BMI View: Although opportunities to invest in Pakistan have improved during recent years, the business environment still suffers f

BMI View: Although Slovenia is a small pharmaceutical market, the country boasts a well-developed healthcare system and solid infr

BMI View: Unlike some observers, BMI classes South Korea as a developed country and this is underpinned by the balanced risk/rewar

BMI View: While we lowered our projections for Hungary's pharmaceutical market in response to the government's structural reform p

BMI View: Latvia’s attractiveness to multinationals will continue to be negatively impacted by the government’s cost-containment m

BMI View: Despite our generally positive outlook for much of Latin America in 2012, we maintain the view that mounting fiscal pres

BMI View: Uncompetitive local drugmakers in Nigeria can only survive with government intervention or investment. This support has

BMI View: Sweden’s pharmaceutical market is expected to grow weakly over the coming years as the government’s attempts to contain

BMI View: We maintain the view that Taiwan is an attractive pharmaceutical market given its relatively large pharmaceutical sector

BMI View: Uzbekistan is Central Asia’s largest market by population, although its pharmaceutical market lags that of neighbouring

BMI View: The overall attractiveness of Vietnam’s pharmaceutical market will continue to be limited by financial and wider regulat

BMI View: We believe the Spanish government's decision to implement further austerity measures is a necessary and prudent course o

BMI View: While the depreciation of the local tender will negatively impact market growth in US dollar terms, the roll-out of the

BMI View: It is now beyond doubt that drugmakers – particularly domestic producers, primarily exposed to their home market – are f

BMI View: Blessed with some of the world's largest reserves of natural resources, many of Latin America's major economies have lon

BMI View: We believe Slovakia's pharmaceutical market is set for an extended period of low growth. In the last year, Slovakia has

BMI View: Globally, Ghana is ranked as the 74th most attractive market for pharmaceutical business, out of a total of 84 countries

BMI View: Locking up doctors and arresting patients suspected of participating in protests will make Bahrain unattractive to local

BMI View: Brazil remains considered the Americas’ most attractive emerging pharmaceutical market, with its potential underpinned b

BMI View: The Canadian pharmaceutical market continues to be a refuge for leading drugmakers. While we foresee cost constraints hi

BMI View: China continues to be one of the world’s most attractive emerging pharmaceutical markets and is primarily driven by a bo

BMI View: India’s pharmaceutical market has entered a brief period of relative deterioration, primarily due to the country’s econo

BMI View: Russia continues to offer both outsized risks and outsized opportunities for foreign drugmakers, according to BMI. Posit

BMI View: Despite the threat of austerity measures, the Swiss government’s focus on cost-containment within the pharmaceuticals an

BMI View: While our outlook for Ukraine's pharmaceutical market remains strong over our five-year forecast period, we continue to

BMI View: From a number of viewpoints, Peru offers considerable rewards to pharmaceutical and healthcare industry players, not lea

BMI View: Saudi Arabia is the largest regional market. While its potential is substantial – given its large population and the hig

BMI View: Hong Kong was in the past an attractive commercial prospect, largely propped by the widespread use of patented medicines

BMI View: Malaysia remains a moderately attractive South-East Asian pharmaceutical market. Key positives include economic developm

BMI View: France is one of the leading global pharmaceutical markets by size, propped up by its large population of just under 63m

BMI View: Serbia’s medium- to-longer term convergence with the wider European market will stimulate pharmaceutical demand, especia

BMI View: Moldova is forecast to deliver a solid US dollar compound annual growth rate (CAGR) of just under 8% for the period 2010

BMI View: A strong economy is expected to drive double-digit annual growth in pharmaceutical sales in Indonesia over our five-year

BMI View: The expected growth of Belgium's ageing population is to have an unprecedented effect on the provision of healthcare. Th

BMI View: Kazakhstan remains by far the most transparent and accessible pharmaceutical market in Central Asia and the government h

BMI View: Oman has a low risk, low reward pharmaceutical market. Key drawbacks include Oman’s strict price controls and small popu

BMI View: The Philippines is a lower/middle income country, where only a minority of the population has access to adequate healthc

BMI View: Portugal is typical of many Western European markets. It is mature, with little scope for growth and is subject to downw

BMI View: Competition is gradually being introduced to Qatar’s pharmaceutical sector, creating opportunities for private sector de

BMI View: The pharmaceutical markets of the seven countries that comprise Central America represent a modest but growing propositi

BMI View: The Colombian healthcare sector's high growth forecast is driven by strong demographics, increased healthcare needs, lon

BMI View: Despite the threat of austerity measures, the government’s focus on cost-containment within the pharmaceuticals and heal

BMI View: The Lebanese market is very different to the other Arabic Gulf Levant countries, if only because pharmaceutical expendit

BMI View: Late-stage revisions to Poland's pharmaceutical reimbursement act have been broadly positive for pharmaceutical companie

BMI View: In terms of its attractiveness to investors, Slovenia remains a mid-tier pharmaceutical market within Emerging Europe. W

BMI View: Taiwan has an attractive pharmaceutical market, aided by its close proximity to China, which is probably the world’s mos

BMI View: Algeria is currently a high-risk market for multinational drugmakers because of the combination of regional political un

BMI View: Argentina's pharmaceutical market, driven by an ageing population and resurgent economic growth, has proven a lucrative

BMI View: Croatia’s pharmaceutical market appears relatively stable, recording 0.1% growth in 2010 – a year in which economic chal

BMI View: Despite the Egyptian interim government's populist spending plans, which include increased budgets for public healthcare

BMI View: We continue to project that the Széll Kálmán structural reforms plan, which aims to achieve savings of HUF120bn (US$580m

BMI View: We see room for moderate growth in Iran's pharmaceuticals industry over the medium term and forecast the market growing

BMI View: Japan’s pharmaceutical market is a compulsory destination for manufacturers of patented drugs and, increasingly, generic

BMI View: Latvia's disease profile and relatively low per-capita consumption of pharmaceuticals (compared with the rest of develop

BMI View: The Netherlands has a well established pharmaceutical industry with strength in vaccines and biologics. As a result, the

BMI View: New Zealand’s pharmaceutical market has a classic low risk, low reward profile. Multinational drugmakers are attracted t

BMI View: There are significant hurdles on multinational's road towards fully exploiting Pakistan's untapped potential, not least

BMI View: Unlike some observers, BMI classes South Korea as a developed country and this is underpinned by the balanced risk/rewar

BMI View: While there is a demand for high-value innovative drugs in Sweden, as highlighted by company and product sales, the fore

BMI View: Uzbekistan has enormous long-term growth potential and is expected to grow by a compound annual growth rate (CAGR) of 11

BMI View: Australian prospects for multinational drugmakers are mixed. In the first quarter of the year it was announced that eigh

BMI View: The Kenyan pharmaceuticals and healthcare market presents significant revenue earning opportunities for drug companies.

BMI View: Thailand pharmaceutical market remains a longer-term attractive market for investors with larger risk capacity. The attr

BMI View: The key drawback to investment in Estonia's pharmaceutical and healthcare market is its small size and moderate outlook

BMI View: Building on rapid expansion over the past five years, Latin America's pharmaceutical market will record stronger medium-

BMI View: A bill to establish the necessary framework for Nigeria’s healthcare system is long overdue. Its timing, just a month af

BMI View: While many innovative pharmaceutical firms have identified pricing policies and weaknesses in Turkey’s intellectual prop

BMI View: The attractiveness of Hong Kong’s pharmaceutical market is threatened by mainland China, which is the world’s most attra

BMI View: Iraq will continue to be viewed as a very challenging investment opportunity. While its longterm commercial potential is

BMI View: Both regionally and globally speaking, Israel boasts high per-capita spending on pharmaceuticals, although the overall m

BMI View: Despite the threat of austerity measures, the Italian government’s focus on cost-containment within the pharmaceuticals

BMI View: Improvements in the drug approvals process and a drug pricing system indicate that regulatory conditions in South Africa

BMI View: President Hugo Chavez's distortive economic policies are increasingly damaging Venezuela's attractiveness to pharmaceuti

BMI View: The pharmaceutical market in Belarus has significant long-term growth potential, but the country’s economy has entered a

BMI View: Given the low per capita spending on pharmaceuticals and widespread corruption, Cambodia will remain of marginal interes

BMI View: In response to the expected passage of key drug policy reforms in the Czech Republic, BMI has cut its projections for ph

BMI View: Ghana is one of the least attractive regional markets in the Middle East and Africa (MEA), judging by our proprietary ME

BMI View: Our view that Greece's pharmaceutical market is set for a decade of decline remains firmly in play. The list of challeng

BMI View: Despite a more positive economic outlook, Lithuania is still considered one of the less attractive pharmaceutical market

BMI View: Following King Abdullah's US$36bn stimulus package all possibility of political unrest in the Kingdom appears to have di

BMI View: The UK faces its most uncertain period in a generation, as the Conservative-Liberal Democrat coalition presses ahead wit

BMI View: Brazil is Latin America’s most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by

BMI View: China remains one of the world’s most attractive emerging pharmaceutical markets. Key drivers include its booming econom

BMI View: Despite real and continued operating risks to pharmaceutical companies present in Russia, BMI maintains the view that th

BMI View: Slovakia is a relatively well-established pharmaceutical market, with fairly limited long-term opportunities for real gr

BMI View: We believe the pharmaceuticals and healthcare sector may be targeted by the government's 2011 cost-containment efforts f

BMI View: Although Sri Lanka is an emerging pharmaceutical market, it boasts relatively welldeveloped healthcare infrastructure an

BMI View: While Bahrain boasts one of the most advanced healthcare systems in the Middle East and Africa (MEA) region, recent poli

BMI View: The Canadian pharmaceutical market is a refuge for the leading drugmakers. It is highly unlikely that punitive price con

BMI View: Blessed with some of the world's largest reserves of natural resources, many of Latin America's major economies have lon

BMI View: France is one of the leading global pharmaceutical markets by size, propped up by its large population, of just short of

BMI View: India's pharmaceutical market is failing to fulfil its potential. Positive attributes include a huge population, a boomi

BMI View: Kuwait remains one of the most attractive regional markets for pharmaceutical investors. Its affluent population has tra

BMI View: Unlike many states in the Middle East and North Africa (MENA) region, Morocco does not have extensive natural oil and ga

BMI View: While Indonesia's pharmaceutical market is small compared with its Asia Pacific neighbours, BMI believes factors such as

BMI View: The key attractions of the Malaysian pharmaceutical market over the longer term are the government’s encouragement of th

BMI View: Moldova’s pharmaceutical market is tiny in absolute terms, although over the next five years we expect it to post respec

BMI View: Regionally speaking, Oman represents a moderately attractive market. While its positives include well-developed healthca

BMI View: Puerto Rico’s high per-capita healthcare and pharmaceutical spending represent a draw for manufacturers of patented drug

BMI View: Despite the threat of austerity measures, the Swiss government’s focus on cost-containment within the pharmaceuticals an

BMI View: Ukraine’s pharmaceutical market will be one of the fastest growing markets in BMI’s Central and Eastern Europe (CEE) cov

BMI View: In 2010, the UAE pharmaceutical market reached a value of AED5.71bn (US$1.56bn). One of the key drivers of growth for th

BMI View: The US pharmaceutical market is a refuge for the leading drugmakers. It is highly unlikely that punitive price controls,

BMI View: Peru is an attractive emerging pharmaceutical market. However, even though we expect the country to outperform its peers

BMI View: Serbia’s return to stronger economic growth will be a considerable driver for the expansion of its pharmaceutical market

BMI View: Singapore is a low-risk pharmaceutical market, propped up by pro-business policies, welldeveloped healthcare provision a

This Special Report from Business Monitor International (BMI) examines the global supply of Molybdenum- 99, looking at the likelih

BMI View: Belgium’s pharmaceutical market is small in absolute size, but compares favourably with other Western European markets i

BMI View: Despite the prospect of lower prices as a result of amendments to the drug reference pricing system, Bulgaria’s pharmace

BMI View: The Colombian healthcare sector's high growth forecast is driven by strong demographics, increased healthcare needs, lon

BMI View: Despite the threat of austerity measures, the government’s focus on cost-containment within the pharmaceuticals and heal

BMI View: Japan's pharmaceutical market is entering a period of low-single digit growth. Demand for medicines will be supported by

BMI View: While Jordan represents a stable market, its modest per-capita spending on pharmaceuticals and a population size of just

BMI View: Kazakhstan has the most liberalised economy in Central Asia and its pharmaceutical industry has long been privatised and

BMI View: Lebanon spends an abnormally large proportion of its national income on pharmaceuticals and healthcare, which makes the

BMI View: The Philippines is a lower/middle income country, where only a minority of the population has access to adequate healthc

BMI View: Portugal is typical of many Western European markets. It is mature, with little scope for growth and is subject to downw

BMI View: Liberalising Qatar's pharmaceutical market will create a competitive pricing system dictated by supply and demand. Multi

BMI View: Zimbabwe remains a very challenging pharmaceutical market, with political and economic difficulties compounded by shortc

BMI View: Bangladesh’s pharmaceutical industry, which was worth US$1.40bn in 2010, is fairly typical for South Asia. Growth is hig

BMI View: Australia's challenging economic situation is affecting its pharmaceutical market. The acceptance of expensive patented

BMI View: Iran remains a challenging market for foreign drugmakers. The difficult political situation will continue to deter forei

BMI View: In terms of its attractiveness to investors, Slovenia remains a mid-tier pharmaceutical market within Emerging Europe. W

BMI View: Unlike some observers, BMI classes South Korea as a developed country and this is underpinned by its pharmaceutical mark

BMI View: Taiwan has an attractive pharmaceutical market, aided by its close proximity to China, which is probably the world’s mos

BMI View: Although offering a very favourable business environment – which is supported by the country's EU membership and relativ

BMI View: Poland’s pharmaceutical market offers good prospects over the medium term combining high single digit growth characteris

BMI View: While Sweden boasts one of the most admirable economies in the world, its pharmaceutical market is not considered as att

BMI View: Uzbekistan is the most populous country in Central Asia and has a rapidly growing economy and a commitment to spend arou

BMI View: Algeria’s state control over pharmaceutical imports and distribution is threatening to destabilise the country’s healthc

BMI View: Argentina's ARS29.14bn (US$7.45bn) pharmaceutical market is a good proposition for pharmaceutical companies. Projected g

BMI View: The Central American healthcare sector's high growth forecast is driven by strong demographics, increased healthcare nee

BMI View: Croatia is considered one of the least attractive pharmaceutical markets within the Emerging Europe region. Key constrai

BMI View: Despite the relatively more stable security environment – compared with February 2011 – we expect political risk in Egyp

BMI View: Estonia is one of the smallest markets in the Emerging Europe region. Its drawbacks include limited population size and

BMI View: We have lowered our projections for Hungary's pharmaceutical market in response to the government's structural reform pr

BMI View: Historical underinvestment in the Kenyan healthcare sector and its high growth forecast – driven by strong demographics,

BMI View: We believe that despite the government’s efforts to improve competitiveness in Mexico’s pharmaceutical sector, persisten

BMI View: Despite the threats posed by austerity measures, the Dutch government’s focus on costcontainment within the pharmaceutic

BMI View: While Nigeria boasts one of the largest populations and fastest growing economies in Africa, its business environment re

BMI View: While Pakistan boasts a substantial population of 174mn people – annual per capita expenditure on pharmaceuticals is ver

BMI View: Thailand is one of the more promising longer-term markets in the Asia Pacific region. Pharmaceutical values and volumes

BMI View: We have lowered our estimates for Turkey's pharmaceutical market and downgraded our medium-term growth projections. Desp

BMI View: Belarus has a potentially attractive pharmaceutical market and ideal geographic placement to access both European Union

BMI View: Despite risks to the Czech Pharmaceutical market posed by upcoming healthcare reforms and unfavourable changes to pricin

BMI View: Cambodia will remain one of the world’s marginally important regional pharmaceutical markets, not least due to widesprea

BMI View: Blessed with some of the world's largest reserves of natural resources, many of Latin America's major economies have lon

BMI View: South Africa’s domestic pharmaceutical and healthcare industries are the most dynamic and successful on the continent. T

BMI View: We expect the UK to introduce regulatory mechanisms to reduce sales recorded by multinational drugmakers. Although the c

BMI View: India's pharmaceutical market beguiles multinational pharmaceutical companies. Sales of medicines are booming and red ta

BMI View: Iraq is viewed as a challenging pharmaceuticals and healthcare market, despite the significant population size, of over

BMI View: We continue to view Lithuania as one of the less attractive Central and Eastern European (CEE) pharmaceutical markets. D

BMI View: President Hugo Chavez's distortive economic policies are increasingly damaging Venezuela's attractiveness to pharmaceuti

BMI View: Bahrain’s pharmaceutical and healthcare system is one of the most advanced and well managed in the region. However, the

BMI View: Faced with unprecedented cuts to publicly-funded medicines, Greece's pharmaceutical industry must prepare for a decade o

Kuwait’s pharmaceutical expenditure stood at around KWD259mn (US$905mn) in 2010. Over the forecast period to 2015, BMI expects the

BMI sees Peru as a regional outperformer in 2011, given the country's strong real GDP growth and the introduction of tax reforms w

BMI View: Slovakia’s pharmaceutical market represents a relatively low risk, but also low reward investment. While per capita expe

BMI View: Spain offers investor positives such as its large drug industry, but the government's costcontainment measures are evide

After days of heavy monsoon rains, Sri Lanka is suffering from severe floods that have killed many and displaced roughly a million

BMI View: Despite the threat of austerity measures, the Swiss government’s focus on cost-containment within the pharmaceuticals an

The United Arab Emirates (UAE) has retained pole position in BMI’s Q211Business Environment Ratings for the Middle East and Africa

In 2010, drug spending in Morocco reached a value of MAD9.14bn (US$1.1bn), posting a local currency year-on-year (y-o-y) growth of

BMI View: Brazil is Latin America’s most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by

In our latest proprietary Pharmaceuticals & Healthcare Business Environment Ratings (BER), France remains ranked fourth out of ten

In the latest edition of our proprietary Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for the 19 markets BMI s

Malaysia's pharmaceutical market potential is likely to be fulfilled in the longer term. For the time being, we view the market as

BMI View: Our forecast for the Russian pharmaceutical market remains robust, seeing 13% US dollar growth over the next five years.

Despite increasingly regulatory interference, the Ukraine pharmaceutical market will continue to boom over the forecast period, wi

Vietnam’s pharmaceutical market was calculated to have been worth US$1.71bn in 2010 at consumer prices. Over the forecast period t

The US economy is finally showing signs of a stronger recovery. We believe that expansion in 2011 could exceed expectations, assis

BMI View: China has the world’s most attractive emerging pharmaceutical market. Driven by a booming economy and underpinned by pol

The primary threat to the Canadian economy in 2011-12 is the increasingly stretched state of household balance sheets, which will

Bangladesh remains in 14th position out of the 17 regional markets surveyed in the Asia region in our latest pharmaceuticals and h

Out of a maximum 100, Belgium scored 64.5 in BMI’s Q211 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), placing

Asia Pacific's attractiveness to multinational drugmakers is faltering. BMI's Pharmaceuticals & Healthcare Business Environment Ra

In our latest regional Business Environment Ratings (BERs), Israel ranks seventh of the 19 markets surveyed in Middle East and Afr

In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Q211, Italy again ranks ninth of the ten markets sur

Moldova’s small market size and its status as one of the poorest countries in Europe will continue to weigh heavily on its score i

Oman’s pharmaceutical market is modest by both regional and global standards. At consumer prices, the market was valued at OMR133m

Portugal’s pharmaceutical market was worth EUR3.59bn (US$4.77bn) in 2010, and drug market expenditure is likely to remain at a sim

BMI View: Predicting the exact outcome of the current popular protests in the Middle East and North Africa (MENA) is impossible at

Supported by the return of stronger economic growth, BMI now projects a more favourable outlook for the Serbian pharmaceutical ind

Singapore has a low risk pharmaceutical market. Despite having an economy that is highly dependent on exports (demand for which is

While Zimbabwe’s difficulties cover the entire economic and political spectrum. Encouraging stabilisation and investment in the ph

Puerto Rico's economy is highly dependent on exports of high-technology products to the US. Due to the islands high exposure to th

In our latest regional Business Environment Ratings (BERs) for the Emerging Europe region, Bulgaria ranks 12th, out of the 20 coun

Colombia has been ravaged by decades of civil conflict and the fighting has internally displaced nearly 3mn people over the years.

Due to its high level of development and the use of patented drugs, Hong Kong continues to be viewed as a relatively attractive As

In our latest regional Business Environment Ratings (BER) matrix, Japan remains the leading pharmaceutical market in the Asia Paci

BMI’s updated forecast for the Kazakhstan pharmaceutical market envisions a compound annual growth rate (CAGR) of 15.43% for 2010-

In BMI's Q211 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), Lebanon remains placed eighth of the 19 markets su

Qatar’s pharmaceutical market was valued at QAR1.43bn (US$392mn) in 2010. Over the next five years, BMI forecasts that drug expend

Pharmaceutical spending in Romania has grown at a rapid pace over the past five years as economic prosperity and improved governme

Costa Rica’s quality of life has deteriorated over recent years, despite former President Óscar Arias taking social spending level

Germany is ranked second in BMI’s Business Environment Ratings (BERs) for Western Europe in Q211 and the country will remain attra

Although the economic situation has been improving, Hungary remains a challenging pharmaceutical destination for multinationals. I

In BMI’s Middle East and Africa Pharmaceutical Business Environment Ratings (BER) for Q211, Iran continued to slip down the rankin

Following a year of negative growth in Jordan’s pharmaceutical market, BMI calculates a return to the positive territory in 2010,

In BMI’s latest Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for the 10 key Western European markets, the Neth

Pakistan’s pharmaceutical expenditure was estimated to be PKR152.97bn (US$1.79bn) in 2010. The country’s pharmaceutical market is

In BMI’s Q211 Business Environment Ratings (BERs), the Philippines is again ranked 11th of the 17 regional markets surveyed in the

In BMI’s Business Environment Ratings (BERs) table for Q211, Slovenia ranks tenth of the 20 markets in the Emerging Europe region.

BMI’s forecast for pharmaceutical expenditure in South Korea has been revised downwards since the last quarter. The factors that c

In BMI’s Pharmaceuticals Business Environment Ratings for Q211, Sweden is the seventh most attractive Western European market surv

Taiwan’s pharmaceutical market is calculated to have reached a value of around TWD129bn (US$4.10bn) in 2010. Through to 2015 and 2

In Q211, we find Algeria has moved down four places to occupy 12th position of the 19 regional markets surveyed in BMI’s Middle Ea

Due to unfavourable government policy and more attractive longer-term prospects offered by other emerging markets, multinational m

The strong growth of the Egyptian pharmaceutical market is an increasingly attractive prospect, as the country is identified as on

Having endured a three-year depression, Latvia is finally gearing up for a return to positive growth in 2011. A number of impressi

Growth in the Mexican pharmaceutical and healthcare sectors will remain strong during 2011, as tax cuts in the US keep external de

Poland now ranks first in our Q211 Pharmaceuticals and Healthcare Business Environment Ratings (BERs) index for the Emerging Europ

For the Q211 update of this report, BMI has revised downwards its projections for Thailand’s once promising pharmaceutical and hea

BMI’s updated pharmaceutical market forecast for Uzbekistan sees a 7.50% US dollar compound annual growth rate (CAGR) for the peri

Argentina's economy is poised for another strong year of growth in 2011, and we are revising up our real GDP growth forecast to 4.

In view of the stronger-than-expected employment situation in Australia, together with the ongoing strength in the commodity marke

In BMI's Q211 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Middle East & Africa region scored an improved

Q211 has proved to be a difficult period for Nigeria’s Pharmaceutical market. In December 2010, leaked US embassy cables indicated

Despite a challenging 2010, with pharmaceutical market growth moderated by the changes to the pricing and reimbursement environmen

The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 a

Blessed with some of the world's largest reserves of natural resources, many of Latin America's major economies have long been rel

Iraq is recovering slowly after the US-led invasion of 2003, but the war – and the years of economic sanctions and neglect before

The UK is ranked second among the 10 Western European markets surveyed in BMI's Business Environment Ratings (BERs) for Q111, movi

The Brazil Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Mexico Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Australia Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors a

The China Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and s

The India Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and s

The Vietnam Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Indonesia Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors a

The Malaysia Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors an

The Singapore Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors a

The Taiwan Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Thailand Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors an

The Philippines Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors

The Greece Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Hungary Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Poland Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Russia Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Romania Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Turkey Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Bulgaria Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors an

The Croatia Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and

The Egypt Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and s

The South Africa Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investor

The United Arab Emirates Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers,

The Saudi Arabia Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investor

The Iran Pharmaceuticals & Healthcare Competitive Intelligence Report is an essential resource for manufacturers, investors and su

The five-year outlook for Lithuania’s pharmaceutical market appears relatively bleak. Recovery from the economic downturn will be

South Africa’s pharmaceutical market was valued at ZAR20.4bn (US$2.4bn) in 2009. By 2014, we forecast that drug spending in the co

India’s pharmaceutical market is highly dynamic and presents significant upsides for both local firms and foreign multinationals.

As we move towards the end of the year, Iraq looks no closer to forming a government. This is set to affect its economic progress,

In BMI's latest regional Pharmaceuticals & Healthcare Business Environment Ratings (BER) matrix for Asia, Sri Lanka receives an un

Higher spending on pharmaceuticals will inflate Morocco’s budget deficit, which is expected to double as a proportion of GDP, from

BMI believes a week local currency will mean a narrow decline in the US dollar value of the Belarusian pharmaceutical market in 20

In BMI’s Q410 Business Environment Ratings (BERs) for the 17 markets of the Americas, Chile receives a composite pharmaceutical ra

Out of a maximum of 100, Belgium scored 65.1 in BMI’s Q410 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), placi

We continue to view Bulgaria as one of the less attractive pharmaceutical markets in the Emerging Europe region. For the Q410 upda

BMI maintains its robust five-year growth forecast for the Kazakhstan pharmaceutical market, which we expect to be driven by recov

Central and Eastern Europe (CEE)'s attractiveness to multinational drugmakers has increased, according to BMI's Pharmaceuticals &

Portugal’s pharmaceutical market was worth EUR3.58bn (US$5.05bn) in 2009, and drug market expenditure is likely to remain at a sim

In BMI’s updated Q410 Business Environment Ratings (BER) for the Middle East and Africa (MEA) region, Qatar is placed 10th out of

In the Q410 update of BMI’s regional Business Environment Ratings (BERs), which assess 19 key markets in the Middle East and Afric

Croatia’s pharmaceutical market, valued at HRK5.74bn (US$1.10bn) in 2009, is calculated to have fallen by 4.95% year-on-year (y-o-

Estonia’s attractiveness to pharmaceutical companies has improved in recent months, as can be seen in BMI’s regional Pharmaceutica

In BMI’s Emerging Europe Business Environment Ratings (BER) for Q410, Hungary continued to improve and is now ranked fourth (out o

Iran’s pharmaceutical market was worth IRN22,765bn (US$2.31bn) in 2009. BMI forecasts a compound annual growth rate (CAGR) of 13%

Latvia’s pharmaceutical market is currently overshadowed by sharp cuts as part of the government’s austerity package, which is aim

BMI calculates that drug sales in the Netherlands reached EUR6.00bn (US$8.45bn) at consumer prices in 2009. Through to 2014, we ex

According to BMI’s Pharmaceutical Expenditure Forecast Model, combined sales of prescription drugs and over-the-counter (OTC) medi

BMI’s growth projection for Uzbekistan’s pharmaceutical market remains largely unchanged this quarter, with its five-year compound

Despite the region’s worsening macroeconomic performance, the business environment for multinational pharmaceutical companies in C

Egypt’s total pharmaceutical spending, which reached EGP13.75bn (US$2.48bn) in 2009, is expected to continue growing steadily over

The value of Argentina’s pharmaceutical market is calculated to have reached ARS12.64bn (US$3.37bn) in 2009. Through to 2014, we f

Measured in local currency terms, Australia’s AUD10.07bn (US$7.74bn) pharmaceutical market is forecast to post a compound annual g

Propped up by its large population, Poland has surfaced as one of the most important global emerging markets, with its value in 20

Pharmaceutical firms have long regarded Nigeria with interest, chiefly because of its massive middleclass population and rising GD

The Philippines remains ranked 11th in our Asia Pacific Business Environment Ratings (BER) table for Q410. Globally, the country p

BMI believes the recent unrest in Thailand will not have an immediate impact on pharmaceutical sales or the revenue earning opport

Along with South Korea, Australia is the joint most attractive pharmaceutical market in Asia Pacific, according to BMI’s Business

According to BMI's drug expenditure forecast model, sales of pharmaceuticals in Sri Lanka are expected to increase from LKR38.97bn

Belarus came through the global economic crisis far more smoothly than neighbours such as Russia and Ukraine, a measure of the cou

In BMI’s Business Environment Ratings for Emerging Europe in Q310, the Czech Republic retained its pole position, which it climbed

BMI’s Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underlines some of our key views for

In BMI's Business Environment Ratings for Q310, the UK has maintained its fifth place out of the ten Western European markets surv

In our updated Q310 Pharmaceutical Business Environment Ratings (BER) for the Americas, Venezuela remains third from the bottom, a

In BMI’s Q310 Business Environment Ratings for the 17 markets of the Americas, Chile receives a composite pharmaceutical rating of

It is BMI's view that India's attractiveness to drugmakers is improving dramatically. According to primary market research firm AI

Our new Q310 Business Environment Ratings (BER) matrix for Emerging Europe places Lithuania in 15th position of the 20 markets sur

BMI’s Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underline some of our key views abou

In the Asia Pacific Pharmaceuticals & Healthcare BERs for Q310, China has maintained fourth position of the 16 markets covered in

Leading Malayisan drugmaker Pharmaniaga expects the outlook for the Malaysian pharmaceutical industry to improve in 2010. This vie

In our Asia Pacific Business Environment Ratings (BER) matrix for Q310, Vietnam remains ranked 13th, out of 16 key regional market

France scores well in our Q310 Pharmaceuticals and Healthcare Business Environment Ratings – it is ranked 10th globally (out of th

Pharmaceutical companies in Greece face unprecedented challenges. The dire fiscal situation in the country is translating into cle

In line with Russia’s economic recovery this year, BMI expects the pharmaceutical sector to post 22.4% US dollar growth in 2010 –

In the BMI emerging Europe pharmaceutical Business Environment Ratings for Q310, Slovakia scored a virtually unchanged 56.7. Howev

In BMI’s Business Environment Ratings for Q310, Spain continued to fall down the matrix. It is now rated eighth out of the 10 coun

Since the last quarter, we have revised our forecast slightly downward for Brazil as a result of concerns over the persisting fisc

In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BER) for Q310, we have significantly expanded the number of co

Puerto Rico’s pharmaceutical market was worth US$2.71bn in 2009 and BMI forecasts this figure to grow at compound annual growth ra

A population of just 738,000 limits the overall pharmaceutical market in Bahrain. In 2009 Bahrain’s pharmaceutical market was wort

In the BMI’s Business Environment Ratings (BER) for the 19 markets in the Middle East and Africa (MEA) region, Ghana receives a co

BMI's Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underlines some of our key views for

In BMI’s updated Americas Business Environment Ratings (BER) for Q310, Canada remains in second place in the expanded regional mat

The outcomes of the US healthcare reforms have generally been viewed negatively by Big Pharma. Despite the potentially profit-limi

In BMI’s Business Environment Rating matrix for Q210, we see Indonesia move up one place to occupy / 12th position out of the 15 r

In BMI’s Asia Pacific Pharmaceutical Business Environment (BER) matrix for Q210, Taiwan maintains / its sixth place, out of the 15

Having received a somewhat lower compound score in Q310, Belgium is now placed joint fifth in the Western Europe Pharmaceuticals

Germany is one of the largest pharmaceutical markets in the world, although market growth has slowed in / recent years as a conseq

Despite a compound annual growth rate (CAGR) of 1.73% in local currency terms and of -0.68% in US / dollar terms from 2004-2009, B

The regional average score for Emerging Europe has improved over the past few months, reaching 49.4 in / Q210, up from 48.7 at the

Pharmaceutical companies in Turkey face considerable challenges in 2010. From being one of the most / prosperous markets in Centra

BMI estimates that Algeria’s pharmaceutical expenditure reached a value of DZD166.05bn (US$2.36bn) / in 2009, rising by 4.5% year-

The total pharmaceutical market in Iran is forecast to increase from US$2.31bn in 2009 to US$3.77bn by / 2014, representing a comp

BMI estimates the Jordanian drug market reached a value of JOD282mn (US$397mn) at consumer prices / in 2009, growing by 7.4% in re

For the Q210 update of the South Korea Pharmaceuticals & Healthcare Report, BMI has changed its primary source of medicine sales d

Romania’s pharmaceutical market remains among the more attractive of the emerging European economies in BMI’s Pharmaceuticals & He

BMI considers Bulgaria to be among the less attractive pharmaceutical markets in Emerging Europe, a view largely enforced by poor

In BMI’s Q210 Business Environment Ratings table for the Americas, Colombia scores 51.7, falling one place to seventh among the 10

The total pharmaceutical market in Qatar will rise from a value of US$233mn in 2009 to US$419mn by 2014, at a CAGR of 12.45%. The

Vietnam’s pharmaceutical market was valued at around VND27,265bn (US$1.53bn) in 2009. Over the next five years, BMI forecasts that

Zimbabwe remains firmly at the bottom of BMI’s Business Environment Ratings for Q310, which looks at 19 key regional markets, now

BMI retains its robust five-year growth forecast for the Kazakhstan pharmaceutical market, with the US dollar value of the market

Portugal’s pharmaceutical sales reached a value of EUR3.62bn (US$5.10bn) in 2009. It is BMI's view that the slowdown in drug mark

In our updated Asia Pacific Business Environment Ratings (BER) table for Q310, the Philippines ranks 11th of the 16 countries surv

BMI’s Pharmaceuticals & Healthcare Business Environment Ratings for Q310 put Poland as the second most attractive market in emergi

Uzbekistan’s pharmaceutical market barely registered the global economic crisis in 2008 and 2009, although the market’s growth rat

In BMI’s new Pharmaceuticals and Healthcare Business Environment Ratings (BER) for Q310, Argentina is ranked seventh in the Americ

Egypt’s total pharmaceutical spending has been on a steady rise, reaching a calculated US$2.48bn by the end of 2009 and forecast t

The outlook for multinational pharmaceutical companies in Central America has improved marginally since Q210 due to a stronger mac

BMI views Estonia’s pharmaceutical market as a mildly attractive proposition for multinational drugmakers. Estonia ranks 11th in B

The value of the Croatia’s pharmaceutical market at consumer prices was calculated to have reached HRK6.14bn (US$1.17bn) in 2009,

In BMI’s Pharmaceutical and Healthcare Business Environment Ratings (BER) for Q310, Hungary continued to improve its placement and

Pharmaceutical spending in Kenya is expected to rise at a compound annual growth rate (CAGR) of 15.69% in local currency terms and

The worsening economic environment resulted in a 7.92% year-on-year (y-o-y) decrease in the value of the Latvian pharmaceutical ma

The value of the total drug market in Mexico will rise from MXN125bn (US$9.26bn) in 2009 to MXN172.66bn (US$16.64bn) by 2014 at a

The outlook for the Netherlands’ drug market is fairly subdued over the next five years. Having been calculated at EUR6bn (US$8.45

Nigeria’s healthcare sector was given a disappointing allocation in the country’s 2010 budget, approved as Acting President Goodlu

Pakistan's US$1.62bn pharmaceutical market is the 10th largest in Asia Pacific, behind the Philippines (US$2.58bn) and ahead of Vi

BMI considers Sweden one of the most attractive markets globally for pharmaceutical companies. Among the 82 countries in BMI’s Glo

In BMI’s Pharmaceutical Business Environment Ratings (BER) table for Q310, Thailand again ranks 10th out of the 16 key markets sur

Out of the 16 key markets surveyed in BMI’s Pharmaceuticals & Healthcare Business Environment Ratings, Bangladesh moves up two pla

The outlook for multinational companies in Brazil has improved over the previous quarter, in line with strong confirmed market gro

BMI calculates that pharmaceutical sales in Chile reached a value of CLP670.34bn in 2009, up from CLP634.82bn in 2008. BMI notes t

Despite a challenging few years, characterised by the introduction of controversial prescription fees and economic downturn, we ca

BMI calculates that total pharmaceutical spending in Greece reached a value of EUR6.24bn (US$8.79bn) in 2009. Expenditure recorded

Kuwait’s pharmaceutical market was estimated to be worth KWD99mn (US$365mn) in 2009. Oil-driven GDP growth is expected to continue

BMI estimates that Oman’s pharmaceutical market was worth US$124mn in 2009 and that it should rise to US$171mn by 2014, representi

BMI expects the Russian pharmaceutical market to rebound from a difficult year in 2009 and return to double-digit growth in 2010.

Slovakia’s pharmaceutical market is among the most attractive in BMI’s Emerging Europe region, ranking fifth in our Pharmaceutical

In BMI’s Business Environment Ratings for Q210, despite its considerable size and strong growth in recent years, Spain continued t

Belarus has endured the global economic crisis far better than most of its Commonwealth of Independent States (CIS) peers, althoug

Despite a compound annual growth rate (CAGR) of 1.77% in local currency terms from 2004-2009, BMI’s outlook for the UK’s drug mark

BMI’s new Ghana pharmaceuticals and healthcare report includes top-line pharmaceutical market and healthcare spending data through

In BMI’s Q210 Pharmaceutical Business Environment Ratings (BER) matrix for Asia Pacific, Cambodia’s immature pharmaceutical market

In BMI’s Business Environment Ratings for Q210, Sweden is ranked third of the 10 Western European markets surveyed. The ratings cr

During early Q210, BMI revised upwards its forecast for medicine sales in India. Combined sales of prescription drugs and over-the

When taken as a whole, the pharmaceutical market of Central America is an attractive prospect for drugmakers. Combined sales of pr

Iraq’s healthcare environment has been damaged considerably as a result of the 2003 coalition invasions and previous conflicts. Du

Healthcare spending in Morocco is expected to rise from US$4.94bn in 2009 to US$6.63bn by 2014 at a CAGR of 6.0% in US dollar term

Having moved up from eighth in Q409 to seventh in Q110, Singapore is now placed ninth (of 15) in BMI’s Asia Pacific Pharmaceutical

In 2009 Bahrain’s pharmaceutical market was worth only BHD43mn (US$112mn), but it is expected to grow to BHD45mn (US$120mn) in 201

Patented drugs prices in Canada have to be approved by 19 bodies, 17 of which are provincial. The Common Drug Review and the feder

In BMI’s updated Q210 Business Environment Rating (BER) matrix for the 10 major pharmaceutical markets in the Americas, Puerto Ric

In February 2010, BMI upgraded China’s patented drug market forecast following clarification of the country’s intellectual propert

Ukraine’s economy suffered its worst one-off decline since the bad old days of the 1990s, with GDP contracting by 15.3%, according

The pharmaceutical market has been one of the strongest performing sectors during the US recession, a sign of the country’s immens

BMI forecasts that the value of Japanese pharmaceutical market at retail prices will increase at a very modest compound annual gro

In BMI’s Business Environment Ratings for Q210, Switzerland remains placed second, having lost its pole position to Germany in Q40

The Israeli pharmaceutical market, worth some ILS6.15bn (US$1.59bn) in 2009, is forecast to grow marginally in the medium term. By

The total pharmaceutical market in Lebanon was worth US$519mn in 2009 and took up 1.71% of GDP, with per-capita spending on medici

In the BMI Business Environment Rating matrix for Q310, we see Indonesia continue to occupy 12th position of the 16 regional marke

Taiwan's US$3.81bn pharmaceutical market is the sixth largest in Asia Pacific, well below Australia (US$8.61bn), but slightly ahea

In our latest Pharmaceutical and Healthcare Business Environment Ratings (BERs), South Korea can be found in pole position of the

In BMI’s Business Environment Ratings (BER) table for Q310, Slovenia is ranked 10th of the 20 markets assessed in the Emerging Eur

Highlighting the effects of the impending patent cliff and the consequent consumption of lower-value generic drugs in place of hig

In BMI’s latest Pharmaceuticals & Healthcare Business Environment Ratings (BER), Italy remains the least attractive Western Europe

BMI calculates the value of Algeria’s pharmaceutical consumption to have been DZD169.55bn (US$2.36bn) in 2009. The market is chara

In BMI’s Middle East and Africa (MEA) Pharmaceutical Business Environment Ratings (BERs) for Q310, Iran is once again found in eig

The Jordan Association of Pharmaceutical Manufacturers states that the pharmaceutical sector in Jordan is export driven, which a g

BMI forecasts that the value of the Argentinean pharmaceutical market will decline in 2009, with the market shrinking almost 10% i

Regulatory pressures have placed considerable pressures on pharmaceutical companies operating in Hungary in recent years. The intr

During 2009, pharmaceutical sales in Kenya reached a value of KES17.92bn, representing a growth of 12.11% in local currency terms.

The total drug market in Mexico will increase from US$9.79bn in 2009 to US$18.96bn by 2014 at a compound annual growth rate (CAGR)

Despite a compound annual growth rate (CAGR) of 4.19% in local currency terms and 6.70% in US dollar terms from 2004-2009, BMI’s o

In BMI’s Q210 update of the Pharmaceutical Business Environment Ratings for the Middle East and Africa (MEA) region, Nigeria remai

Having been ranked as the 11th most attractive pharmaceutical market in the Asia Pacific region in Q110, the Philippines improved

BMI considers Poland’s pharmaceutical market reasonably attractive to multinational pharmaceutical companies. In BMI’s Q210 Busine

Thailand’s pharmaceutical market is expected to grow by 7.7% in 2009. Although this is below the 2004- 08 compound annual growth r

Of the 15 key markets surveyed in BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs), Bangladesh can be found

Pakistan’s macroeconomic indicators have deteriorated significantly since Q110. The rupee has depreciated against the US dollar, G

Croatia’s pharmaceutical market, valued at around HRK6.14bn (US$1.17bn) in 2009, is estimated to have grown by 6.55% in local curr

In BMI’s regional Business Environment Ratings (BER) matrix for Q210, Estonia is ranked 12th of the 20 key markets within Emerging

BMI calculates the Latvian pharmaceutical market to have been worth LVL244mn (US$482mn) in 2009, assuming a year-on-year (y-o-y) d

Uzbekistan retains its position as both one of the most promising and risky pharmaceutical markets in Central and Eastern Europe (

Egypt’s total pharmaceutical spending has been on a steady rise, reaching a calculated US$2.47bn by the end of 2009 and forecast t

In BMI’s Q310 Business Environment Ratings (BER) table for the expanding Americas matrix, Colombia occupies sixth position (up fro

In BMI’s Business Environment Ratings (BER) table for Q310, Singapore is ranked fifth of the 16 markets assessed in the Asia Pacif

Ukraine’s pharmaceutical market is moving toward strong recovery in 2010, with BMI forecasting a 21.5% US dollar rebound to follow

The outlook for multinational pharmaceutical companies in Central America has improved marginally since Q210 due to a stronger mac

BMI views Estonia’s pharmaceutical market as a mildly attractive proposition for multinational drugmakers. Estonia ranks 11th in B

The value of the Croatia’s pharmaceutical market at consumer prices was calculated to have reached HRK6.14bn (US$1.17bn) in 2009,

In BMI’s Pharmaceutical and Healthcare Business Environment Ratings (BER) for Q310, Hungary continued to improve its placement and

Pharmaceutical spending in Kenya is expected to rise at a compound annual growth rate (CAGR) of 15.69% in local currency terms and

The worsening economic environment resulted in a 7.92% year-on-year (y-o-y) decrease in the value of the Latvian pharmaceutical ma

The outlook for the Netherlands’ drug market is fairly subdued over the next five years. Having been calculated at EUR6bn (US$8.45

Pakistan's US$1.62bn pharmaceutical market is the 10th largest in Asia Pacific, behind the Philippines (US$2.58bn) and ahead of Vi

BMI considers Sweden one of the most attractive markets globally for pharmaceutical companies. Among the 82 countries in BMI’s Glo

In BMI’s Pharmaceutical Business Environment Ratings (BER) table for Q310, Thailand again ranks 10th out of the 16 key markets sur